New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAHK-Cu vs Retatrutide

AHK-Cu vs Retatrutide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
AHK-Cu
GLP-1 / Weight Loss Agonists
Retatrutide
Summary
AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Half-Life
Hours (topical, variable by formulation)
~10–12 days
Admin Route
Topical, Scalp application, Subcutaneous (research)
SubQ
Research
Typical Dose
0.01–0.1% concentration
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
Frequency
Once or twice daily
Once weekly
Key Benefits
  • Stimulates hair follicle growth and reduces shedding
  • Increases dermal papilla cell proliferation
  • Promotes wound healing and skin regeneration
  • Antioxidant protection via superoxide dismutase activation
  • Improves skin elasticity and firmness
  • Supports collagen and elastin production
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
Side Effects
  • Generally well-tolerated topically
  • Mild scalp irritation or redness in sensitive individuals
  • Possible temporary hair shedding phase at treatment initiation
  • Copper accumulation with excessive systemic use (rare)
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
Stacks With